June 26, 2026, Everest Medicines today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL(R) (lerodalcibep), a...
Everest Medicines (HKEX 1952.HK) announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules,...
China Medical System Holdings Limited (867.HK/8A8.SG) (CMS, or the Group) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the...
Group sharpens focus on aesthetics retail under the CEO's first initiative, a proposed entry into the Xiamen aesthetic clinic market
Accrelist Ltd. (“Accrelist” or the...
Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (Dimerix), for the development and commercialization of...
Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration...
